BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ;  CROWN Trial Investigators. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med. 2020;383:2018-2029. [PMID: 33207094 DOI: 10.1056/nejmoa2027187] [Cited by in Crossref: 276] [Cited by in F6Publishing: 300] [Article Influence: 92.0] [Reference Citation Analysis]
Number Citing Articles
1 Lee M, Abu Rous F, Borczuk A, Liu S, Gadgeel S, Halmos B. Targeting Oncogenic Driver Mutations in Lung Cancer. 2023. [DOI: 10.1017/9781009336123] [Reference Citation Analysis]
2 de Leeuw SP, de Bruijn P, Koolen SLW, Dingemans AC, Mathijssen RHJ, Veerman GDM. Quantitation of osimertinib, alectinib and lorlatinib in human cerebrospinal fluid by UPLC-MS/MS. J Pharm Biomed Anal 2023;225:115233. [PMID: 36638566 DOI: 10.1016/j.jpba.2023.115233] [Reference Citation Analysis]
3 Zhang X, Zhang L. Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade. JAMA Oncol 2023. [PMID: 36729440 DOI: 10.1001/jamaoncol.2022.7583] [Reference Citation Analysis]
4 Naso J, Lo YC, Sholl LM. Updates in pathology and molecular diagnostics to inform the evolving landscape of thoracic surgery and oncology. J Surg Oncol 2023;127:244-57. [PMID: 36630101 DOI: 10.1002/jso.27184] [Reference Citation Analysis]
5 Qie Y, Cheng Z, Wu Z, Qi F, Li B, Wu S, Chu T, Lu Z, Li S, Nie G. Identification of protein kinase C beta as a therapeutic target for neuroendocrine prostate cancer and development of a nanoparticle-based therapeutic strategy. Nano Today 2023;48:101705. [DOI: 10.1016/j.nantod.2022.101705] [Reference Citation Analysis]
6 Nagasaka M, Ou SI. CROWN 2022 Second Interim Updates: When Will Be the Coronation of Lorlatinib? J Thorac Oncol 2023;18:139-42. [PMID: 36460598 DOI: 10.1016/j.jtho.2022.10.019] [Reference Citation Analysis]
7 Peng H, Li X, Luan Y, Wang C, Wang W. A novel prognostic model related to oxidative stress for treatment prediction in lung adenocarcinoma. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1078697] [Reference Citation Analysis]
8 Manselle MK, Ries RE, Hylkema T, Leonti A, Kirkey DC, Furlan SN, Meshinchi S. Functional consequence and therapeutic targeting of cryptic ALK fusions in monosomy 7 acute myeloid leukemia. Pediatr Blood Cancer 2023;:e30180. [PMID: 36720638 DOI: 10.1002/pbc.30180] [Reference Citation Analysis]
9 D’aiello A, Miao E, Cheng H. Advances in the Management of Central Nervous System Metastases in Non-Small Cell Lung Cancer. Cancers 2023;15:844. [DOI: 10.3390/cancers15030844] [Reference Citation Analysis]
10 Katayama Y, Yamada T, Tanimura K, Tokuda S, Morimoto K, Hirai S, Matsui Y, Nakamura R, Ishida M, Kawachi H, Yoneda K, Hosoya K, Tsuji T, Ozasa H, Yoshimura A, Iwasaku M, Kim YH, Horinaka M, Sakai T, Utsumi T, Shiotsu S, Takeda T, Katayama R, Takayama K. Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer. NPJ Precis Oncol 2023;7:12. [PMID: 36702855 DOI: 10.1038/s41698-023-00350-7] [Reference Citation Analysis]
11 Otano I, Ucero AC, Zugazagoitia J, Paz-Ares L. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC. Nat Rev Clin Oncol 2023. [PMID: 36639452 DOI: 10.1038/s41571-022-00718-x] [Reference Citation Analysis]
12 Xu T, Karschnia P, Cadilha BL, Dede S, Lorenz M, Seewaldt N, Nikolaishvili E, Müller K, Blobner J, Teske N, Herold JJ, Rejeski K, Langer S, Obeck H, Lorenzini T, Mulazzani M, Zhang W, Ishikawa-Ankerhold H, Buchholz VR, Subklewe M, Thon N, Straube A, Tonn JC, Kobold S, von Baumgarten L. In vivo dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancer. Oncoimmunology 2023;12:2163781. [PMID: 36687005 DOI: 10.1080/2162402X.2022.2163781] [Reference Citation Analysis]
13 Li J, Han S, Zhu Y, Dong B. Halorotetin A: A Novel Terpenoid Compound Isolated from Ascidian Halocynthia rotetzi Exhibits the Inhibition Activity on Tumor Cell Proliferation. Mar Drugs 2023;21. [PMID: 36662224 DOI: 10.3390/md21010051] [Reference Citation Analysis]
14 Ozcan G, Singh M, Vredenburgh JJ. Leptomeningeal Metastasis from Non-Small Cell Lung Cancer and Current Landscape of Treatments. Clin Cancer Res 2023;29:11-29. [PMID: 35972437 DOI: 10.1158/1078-0432.CCR-22-1585] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Lin HM, Wu Y, Yin Y, Niu H, Curran EA, Lovly CM, Humphries MJ. Real-world ALK Testing Trends in Patients With Advanced Non-Small-Cell Lung Cancer in the United States. Clin Lung Cancer 2023;24:e39-49. [PMID: 36376172 DOI: 10.1016/j.cllc.2022.09.010] [Reference Citation Analysis]
16 Pruis MA, Veerman GM, Hassing HC, Lanser DA, Paats MS, van Schaik RH, Mathijssen RH, Manintveld O, Dingemans AC. Cardiac Side Effects of Alectinib in Patients With ALK-Positive Lung Cancer. JACC: CardioOncology 2023. [DOI: 10.1016/j.jaccao.2022.09.006] [Reference Citation Analysis]
17 Schmid S, Cheng S, Chotai S, Garcia M, Zhan L, Hueniken K, Balaratnam K, Khan K, Patel D, Grant B, Raptis R, Brown MC, Xu W, Moriarty P, Shepherd FA, Sacher AG, Leighl NB, Bradbury PA, Liu G. Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer. Clin Lung Cancer 2023;24:40-50. [PMID: 36270866 DOI: 10.1016/j.cllc.2022.09.007] [Reference Citation Analysis]
18 Chung EK, Yong SH, Lee EH, Kim EY, Chang YS, Lee SH. New Targeted Therapy for Non-Small Cell Lung Cancer. Tuberc Respir Dis (Seoul) 2023;86:1-13. [PMID: 36196556 DOI: 10.4046/trd.2022.0066] [Reference Citation Analysis]
19 Arbitrio M, Cordua A, Uppolo V, D’apolito M, Caracciolo D, Staropoli N, Cuomo O, Fiorillo L, Tassone P, Di Martino M, Tagliaferri P. What is precision medicine in oncology? Liquid Biopsy 2023. [DOI: 10.1016/b978-0-12-822703-9.00002-8] [Reference Citation Analysis]
20 Jia K, Ren S. Neurocognitive Adverse Events of Lorlatinib: On the Way to Precise Prediction? J Thorac Oncol 2023;18:26-8. [PMID: 36543433 DOI: 10.1016/j.jtho.2022.11.003] [Reference Citation Analysis]
21 Hendriks L, Kerr K, Menis J, Mok T, Nestle U, Passaro A, Peters S, Planchard D, Smit E, Solomon B, Veronesi G, Reck M. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology 2023. [DOI: 10.1016/j.annonc.2022.12.009] [Reference Citation Analysis]
22 Wahida A, Buschhorn L, Fröhling S, Jost PJ, Schneeweiss A, Lichter P, Kurzrock R. The coming decade in precision oncology: six riddles. Nat Rev Cancer 2023;23:43-54. [PMID: 36434139 DOI: 10.1038/s41568-022-00529-3] [Reference Citation Analysis]
23 Wilcox JA, Boire AA. Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases. CNS Drugs 2023;37:45-67. [PMID: 36474108 DOI: 10.1007/s40263-022-00975-5] [Reference Citation Analysis]
24 Dagogo-Jack I, Abbattista A, Murphy JF, Krulewicz S, Do A, Peterson J, Lin JJ, Gainor JF, Messina R, Krueger EA, Thurm H, Yeap BY. Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies. J Thorac Oncol 2023;18:67-78. [PMID: 36184067 DOI: 10.1016/j.jtho.2022.09.219] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Rossi S, Marinello A, Pagliaro A, Franceschini D, Navarria P, Finocchiaro G, Toschi L, Scorsetti M, Santoro A. Current treatment approaches for brain metastases in ALK/ROS1/NTRK-positive non-small-cell lung cancer. Expert Rev Anticancer Ther 2023;23:29-41. [PMID: 36548111 DOI: 10.1080/14737140.2023.2162044] [Reference Citation Analysis]
26 Watanabe S, Sakai K, Matsumoto N, Koshio J, Ishida A, Abe T, Ishikawa D, Tanaka T, Aoki A, Kajiwara T, Koyama K, Miura S, Goto Y, Sekiya T, Suzuki R, Kushiro K, Fujisaki T, Yanagimura N, Ohtsubo A, Shoji S, Nozaki K, Saida Y, Yoshizawa H, Nishio K, Kikuchi T. Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501). Cancers (Basel) 2022;15. [PMID: 36612200 DOI: 10.3390/cancers15010204] [Reference Citation Analysis]
27 Nagahisa Y, Sumi T, Sekikawa M, Takeda K, Matsuura K, Watanabe H, Yamada Y, Keira Y, Chiba H. Two Cases of ALK Fusion Gene-positive Lung Adenocarcinoma Treated with Brigatinib After Alectinib-induced Interstitial Lung Disease. JJLC 2022;62:1038-1043. [DOI: 10.2482/haigan.62.1038] [Reference Citation Analysis]
28 Ozawa R, Kuraishi H, Takeuchi Y, Tanaka S, Yamamoto M, Hase I, Masubuchi T, Satomi H, Ito I, Koyama S. An Anaplastic Lymphoma Kinase-rearranged Squamous Cell Lung Cancer Treated with Sequential ALK-tyrosine Kinase Inhibitor Therapy: a Case Report. JJLC 2022;62:1001-1008. [DOI: 10.2482/haigan.62.1001] [Reference Citation Analysis]
29 Zhou S, Shen C, Che G. [Research Progress of Treatment for NSCLC in Young Patients]. Zhongguo Fei Ai Za Zhi 2022;25:888-94. [PMID: 36617475 DOI: 10.3779/j.issn.1009-3419.2022.102.48] [Reference Citation Analysis]
30 Li R, Liu M, Yang Z, Li J, Gao Y, Tan R. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future. Molecules 2022;27. [PMID: 36557960 DOI: 10.3390/molecules27248828] [Reference Citation Analysis]
31 Wang Z, Xing Y, Li B, Li X, Liu B, Wang Y. Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. Mol Biomed 2022;3:42. [PMID: 36508072 DOI: 10.1186/s43556-022-00107-x] [Reference Citation Analysis]
32 Qiu Y, Song L, Jiang G, Zhang Z, Liu X, Wang G. Hallmarks of Anaplastic Lymphoma Kinase Inhibitors with Its Quick Emergence of Drug Resistance. Pharmaceutical Fronts 2022. [DOI: 10.1055/s-0042-1758542] [Reference Citation Analysis]
33 Park MK, Lim JM, Jeong J, Jang Y, Lee JW, Lee JC, Kim H, Koh E, Hwang SJ, Kim HG, Kim KC. Deep-Learning Algorithm and Concomitant Biomarker Identification for NSCLC Prediction Using Multi-Omics Data Integration. Biomolecules 2022;12. [PMID: 36551266 DOI: 10.3390/biom12121839] [Reference Citation Analysis]
34 Cicin I, Martin C, Haddad CK, Kim S, Smolin A, Abdillah A, Yang X. ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences. Critical Reviews in Oncology/Hematology 2022;180:103847. [DOI: 10.1016/j.critrevonc.2022.103847] [Reference Citation Analysis]
35 Agüloğlu N, Aksu A, Unat DS, Akyol M. The prognostic relationship of 18F-FDG PET/CT metabolic and volumetric parameters in metastatic ALK + NSCLC. Nuclear Medicine Communications 2022;43:1217-1224. [DOI: 10.1097/mnm.0000000000001625] [Reference Citation Analysis]
36 Wu J, Lin Z. Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance. Int J Mol Sci 2022;23. [PMID: 36499382 DOI: 10.3390/ijms232315056] [Reference Citation Analysis]
37 Skaugen JM, Taneja C, Liu JB, Wald AI, Nikitski AV, Chiosea SI, Seethala RR, Ohori NP, Karslioglu-French E, Carty SE, Nikiforova MN, Yip L, Nikiforov YE. Performance of a Multigene Genomic Classifier in Thyroid Nodules with Suspicious for Malignancy Cytology. Thyroid 2022;32:1500-8. [PMID: 35864811 DOI: 10.1089/thy.2022.0282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Heinzen S, Reis H, Sebastian M, Demes M, Stratmann J. State of the Art: onkogen alteriertes nichtkleinzelliges Lungenkarzinom im Stadium IV. Onkologie 2022;28:1087-1094. [DOI: 10.1007/s00761-022-01248-y] [Reference Citation Analysis]
39 Ahn MJ, Kim HR, Yang JCH, Han JY, Li JY, Hochmair MJ, Chang GC, Delmonte A, Lee KH, Campelo RG, Gridelli C, Spira AI, Califano R, Griesinger F, Ghosh S, Felip E, Kim DW, Liu Y, Zhang P, Popat S, Camidge DR. Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study. Clin Lung Cancer 2022;23:720-30. [PMID: 36038416 DOI: 10.1016/j.cllc.2022.07.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, Goto Y, Kim D, Wu Y, Jassem J, López FL, Soo RA, Shaw AT, Polli A, Messina R, Iadeluca L, Toffalorio F, Felip E. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. The Lancet Respiratory Medicine 2022. [DOI: 10.1016/s2213-2600(22)00437-4] [Reference Citation Analysis]
41 Mazieres J, Iadeluca L, Shaw AT, Solomon BJ, Bauer TM, de Marinis F, Felip E, Goto Y, Kim DW, Mok T, Reisman A, Thurm H, Polli AM, Liu G. Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer. Lung Cancer 2022;174:146-56. [PMID: 36410210 DOI: 10.1016/j.lungcan.2022.11.004] [Reference Citation Analysis]
42 Lin JJ, Gainor JF. First-line lorlatinib for advanced ALK-positive non-small-cell lung cancer. The Lancet Respiratory Medicine 2022. [DOI: 10.1016/s2213-2600(22)00488-x] [Reference Citation Analysis]
43 Ghannam Y, Laville A, Kirova Y, Latorzeff I, Levy A, Zhou Y, Bourbonne V. Radiotherapy of the Primary Disease for Synchronous Metastatic Cancer: A Systematic Review. Cancers (Basel) 2022;14. [PMID: 36497410 DOI: 10.3390/cancers14235929] [Reference Citation Analysis]
44 Zhong WX, Wei XF. Coexistence of anaplastic lymphoma kinase rearrangement in lung adenocarcinoma harbouring epidermal growth factor receptor mutation: A single-center study. World J Clin Cases 2022; 10(33): 12164-12174 [DOI: 10.12998/wjcc.v10.i33.12164] [Reference Citation Analysis]
45 Min Y, Liu Z, Wei Z, Li R, Jin J, Zhang Y, Peng X. Association between Statin Use and Survival in Cancer Patients with Brain Metastasis: Retrospective Analysis from the Chinese Population. Pharmaceuticals (Basel) 2022;15. [PMID: 36558925 DOI: 10.3390/ph15121474] [Reference Citation Analysis]
46 Wang Z, Han Y, Tao H, Xu M, Liu Z, Zhu J, Li W, Ma J, Liu Z, Wang W, Ma T. Molecular characterization of genomic breakpoints of ALK rearrangements in non-small cell lung cancer. Mol Oncol 2022. [PMID: 36423218 DOI: 10.1002/1878-0261.13348] [Reference Citation Analysis]
47 Barbieri MA, Sorbara EE, Cicala G, Santoro V, Cutroneo PM, Franchina T, Santarpia M, Silvestris N, Spina E. Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database. Front Oncol 2022;12:1005626. [PMID: 36505840 DOI: 10.3389/fonc.2022.1005626] [Reference Citation Analysis]
48 Zhao J, Li X, Fan R, Qin Y, Wang Z, Wang B, Li S, Fan J, Wu X, Liu H, Guan Y, Liang Y, Zhang X, Guo Y. Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report. Front Pharmacol 2022;13:1060460. [PMID: 36506539 DOI: 10.3389/fphar.2022.1060460] [Reference Citation Analysis]
49 Li N, Xie M, Zhou Z, Sheng J, Yu X, Fan Y. Real-world treatment and prognostic factors for survival in ALK+ non-small cell lung cancer (NSCLC) patients with brain metastases in China. Thorac Cancer 2023;14:237-45. [PMID: 36411716 DOI: 10.1111/1759-7714.14739] [Reference Citation Analysis]
50 Melichar B. Biomarkers in the management of lung cancer: changing the practice of thoracic oncology. Clinical Chemistry and Laboratory Medicine (CCLM) 2022;0. [DOI: 10.1515/cclm-2022-1108] [Reference Citation Analysis]
51 Leighow SM, Landry B, Lee MJ, Peyton SR, Pritchard JR. Agent-Based Models Help Interpret Patterns of Clinical Drug Resistance by Contextualizing Competition Between Distinct Drug Failure Modes. Cel Mol Bioeng 2022. [DOI: 10.1007/s12195-022-00748-6] [Reference Citation Analysis]
52 Tsui DCC, Drusbosky LM, Wienke S, Gao D, Bubie A, Barbacioru C, Camidge DR. Oncogene Overlap Analysis of Circulating Cell-free Tumor DNA to Explore the Appropriate Criteria for Defining MET Copy Number-Driven Lung Cancer. Clin Lung Cancer 2022;23:630-8. [PMID: 35961935 DOI: 10.1016/j.cllc.2022.07.002] [Reference Citation Analysis]
53 Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43:4229-361. [PMID: 36017568 DOI: 10.1093/eurheartj/ehac244] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 65.0] [Reference Citation Analysis]
54 Tao J, Zheng C, Zhang C, Zhou L, Liu Z, Zhou Y, Huang X, Lin L, Zhai L. First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis. J Int Med Res 2022;50:030006052211327. [DOI: 10.1177/03000605221132703] [Reference Citation Analysis]
55 Reutova EV. Lorlatinib: new therapeutic options for ALK-positive patients. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-22-2] [Reference Citation Analysis]
56 Soumerai JD, Rosenthal A, Harkins S, Duffy J, Mecca C, Wang Y, Grewal RK, El-Jawahri AR, Liu H, Menard C, Dogan A, Yang L, Rimsza LM, Bantilan K, Martin H, Lei M, Mohr S, Kurilovich A, Kudryashova O, Postovalova E, Nardi V, Abramson JS, Chiarle R, Zelenetz AD, Louissaint A Jr. Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. Blood 2022;140:1822-6. [PMID: 35802834 DOI: 10.1182/blood.2022015443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Liu GH, Chen T, Zhang X, Ma XL, Shi HS. Small molecule inhibitors targeting the cancers. MedComm (2020) 2022;3:e181. [PMID: 36254250 DOI: 10.1002/mco2.181] [Reference Citation Analysis]
58 Guo H, Zhang J, Qin C, Yan H, Liu T, Hu H, Tang S, Tang S, Zhou H. Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives. Cells 2022;11:3200. [DOI: 10.3390/cells11203200] [Reference Citation Analysis]
59 Yan T, Tian X, Liu F, Liu Q, Sheng Q, Wu J, Jiang S. The emerging role of circular RNAs in drug resistance of non-small cell lung cancer. Front Oncol 2022;12:1003230. [DOI: 10.3389/fonc.2022.1003230] [Reference Citation Analysis]
60 Doi Y, Tagaya H, Noge A, Semba K. Prediction of Resistance Mutations Against Upcoming Anaplastic Lymphoma Kinase Inhibitors. Target Oncol 2022. [PMID: 36201110 DOI: 10.1007/s11523-022-00919-5] [Reference Citation Analysis]
61 Yamada T, Katayama Y, Tanimura K, Tokuda S, Morimoto K, Hirai S, Matsui Y, Nakamura R, Ishida M, Kawachi H, Yoneda K, Hosoya K, Tsuji T, Ozasa H, Yoshimura A, Iwasaku M, Kim Y, Horinaka M, Sakai T, Takayama K. Adaptive Resistance to Lorlatinib via EGFR Signaling in ALK-rearranged Lung Cancer.. [DOI: 10.21203/rs.3.rs-2089228/v1] [Reference Citation Analysis]
62 Xue F, Xu S, Jiang C, Kang M, Usman M, Zhu L. Case report: Novel junctional sarcoplasmic reticulum protein 1 intergenic region–anaplastic lymphoma kinase fusion in a patient with lung adenocarcinoma responds to alectinib. Front Oncol 2022;12:1019624. [DOI: 10.3389/fonc.2022.1019624] [Reference Citation Analysis]
63 Aaron RM, Low HK, Sokol BT, Dounay AB. Lorlatinib (Lorbrena), An ALK Inhibitor for Treating NSCLC. Current Drug Synthesis 2022. [DOI: 10.1002/9781119847281.ch11] [Reference Citation Analysis]
64 Singh N, Temin S, Baker S Jr, Blanchard E, Brahmer JR, Celano P, Duma N, Ellis PM, Elkins IB, Haddad RY, Hesketh PJ, Jain D, Johnson DH, Leighl NB, Mamdani H, Masters G, Moffitt PR, Phillips T, Riely GJ, Robinson AG, Rosell R, Schiller JH, Schneider BJ, Spigel DR, Jaiyesimi IA. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline. J Clin Oncol 2022;40:3310-22. [PMID: 35816666 DOI: 10.1200/JCO.22.00824] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
65 Duruisseaux M, Descourt R, Moro-sibilot D. Les patients ALK et ROS1 : quelle séquence ? Revue des Maladies Respiratoires Actualités 2022;14:2S178-2S188. [DOI: 10.1016/s1877-1203(22)00118-5] [Reference Citation Analysis]
66 Quinn ZL, Barta JA, Johnson JM. Molecular lung cancer: How targeted therapies and personalized medicine are re-defining cancer care. Am J Med Sci 2022;364:371-8. [PMID: 35469765 DOI: 10.1016/j.amjms.2022.04.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
67 Wilcox JA, Li MJ, Boire AA. Leptomeningeal Metastases: New Opportunities in the Modern Era. Neurotherapeutics 2022;19:1782-98. [PMID: 35790709 DOI: 10.1007/s13311-022-01261-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Cognigni V, Pecci F, Lupi A, Pinterpe G, De Filippis C, Felicetti C, Cantini L, Berardi R. The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives. Cancers 2022;14:4765. [DOI: 10.3390/cancers14194765] [Reference Citation Analysis]
69 Gao X, Zhang W, Jia Y, Xu H, Zhu Y, Pei X. Identification of a prognosis-related ceRNA network in cholangiocarcinoma and potentially therapeutic molecules using a bioinformatic approach and molecular docking. Sci Rep 2022;12:16247. [PMID: 36171401 DOI: 10.1038/s41598-022-20362-w] [Reference Citation Analysis]
70 . Lung Cancer. Fundamentals of Cancer Detection, Treatment, and Prevention 2022. [DOI: 10.1002/9783527838561.ch11] [Reference Citation Analysis]
71 Wu Y, Ren K, Wan Y, Lin HM. Economic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors. J Oncol Pharm Pract 2022;:10781552221126174. [PMID: 36131505 DOI: 10.1177/10781552221126174] [Reference Citation Analysis]
72 Luo X, Zhou Z, Zeng X, Peng L, Liu Q. Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China. Front Public Health 2022;10:985834. [PMID: 36211665 DOI: 10.3389/fpubh.2022.985834] [Reference Citation Analysis]
73 Ashrafi A, Akter Z, Modareszadeh P, Modareszadeh P, Berisha E, Alemi PS, Chacon Castro MDC, Deese AR, Zhang L. Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance. Cancers 2022;14:4562. [DOI: 10.3390/cancers14194562] [Reference Citation Analysis]
74 Aguado de la Rosa C, Cruz Castellanos P, Lázaro-Quintela M, Dómine M, Vázquez Estévez S, López-Vivanco G, Fírvida Pérez JL, Alonso Romero JL, Ferrera Delgado L, García Girón C, Diz Taín P, Álvarez Álvarez R, Mut Sanchís P, Fernández Cantón I, Manrique Abós I, Martínez Aguillo M, Gómez-Aldaraví Gutiérrez L, Ortega Granados AL, Álvarez Cabellos R, García Sebastián A, García Sifuentes LF, Reguart N. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study). Lung Cancer 2022;173:83-93. [PMID: 36162227 DOI: 10.1016/j.lungcan.2022.09.010] [Reference Citation Analysis]
75 Jiang J, Zhao C, Zhang F, Liu Z, Zhou K, Ren X, Wan Y. ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis. BMJ Open 2022;12:e060782. [PMID: 36123063 DOI: 10.1136/bmjopen-2022-060782] [Reference Citation Analysis]
76 Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun (Lond) 2022. [PMID: 36075878 DOI: 10.1002/cac2.12359] [Reference Citation Analysis]
77 Mesquita FP, Souza PFN, da Silva EL, Lima LB, de Oliveira LLB, Moreira-nunes CA, Zuercher WJ, Burbano RMR, de Moraes MEA, Montenegro RC. Kinase Inhibitor Screening Displayed ALK as a Possible Therapeutic Biomarker for Gastric Cancer. Pharmaceutics 2022;14:1841. [DOI: 10.3390/pharmaceutics14091841] [Reference Citation Analysis]
78 Gettinger SN, Huber RM, Kim D, Bazhenova L, Hansen KH, Tiseo M, Langer CJ, Paz-ares Rodríguez LG, West HL, Reckamp KL, Weiss GJ, Smit EF, Hochmair MJ, Kim S, Ahn M, Kim ES, Groen HJ, Pye J, Liu Y, Zhang P, Vranceanu F, Camidge DR. Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials. JTO Clinical and Research Reports 2022;3:100385. [DOI: 10.1016/j.jtocrr.2022.100385] [Reference Citation Analysis]
79 Pasquier C, Basse C. Nouvelles AMMs : lorlatinib dans le traitement des cancers bronchiques non à petites cellules avec translocation ALK en première ligne. Bulletin du Cancer 2022;109:877-878. [DOI: 10.1016/j.bulcan.2022.04.006] [Reference Citation Analysis]
80 Ma Y, Zhao H, Xue J, Liu L, Yang N, Zhang Y, Yang H, Hong S, Xiong Y, Zhang Z, Zeng L, Pan H, Zhou C, Zhang Y, Wang X, Han X, Wan X, Shao Y, Liu J, Yang Y, Huang Y, Zhao Y, Fang W, Li S, Zhang L. First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements. Eur J Cancer 2022;173:238-49. [PMID: 35940055 DOI: 10.1016/j.ejca.2022.06.037] [Reference Citation Analysis]
81 Verdura S, Encinar JA, Fernández-arroyo S, Joven J, Cuyàs E, Bosch-barrera J, Menendez JA. Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells. IJMS 2022;23:9986. [DOI: 10.3390/ijms23179986] [Reference Citation Analysis]
82 Zhao B, Ma W. Continuation of Lorlatinib May Bring Benefits to ALK-Positive NSCLC Beyond Progressive Disease; More Things Should Be Considered. J Thorac Oncol 2022;17:e85-6. [PMID: 36031298 DOI: 10.1016/j.jtho.2022.01.020] [Reference Citation Analysis]
83 Fountzilas E, Tsimberidou AM, Vo HH, Kurzrock R. Clinical trial design in the era of precision medicine. Genome Med 2022;14:101. [PMID: 36045401 DOI: 10.1186/s13073-022-01102-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Wen Y, Jiang T, Wu X, Peng H, Ren S, Zhou C. Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis. Ther Adv Med Oncol 2022;14:17588359221116607. [PMID: 36032351 DOI: 10.1177/17588359221116607] [Reference Citation Analysis]
85 Li Q, Jiang Y, Song N, Zhou B, Li Z, Lin L, Ali Sheikh MS. An Immune-Related Genetic Feature Depicted the Heterogeneous Nature of Lung Adenocarcinoma and Squamous Cell Carcinoma and Their Distinctive Predicted Drug Responses. Oxidative Medicine and Cellular Longevity 2022;2022:1-23. [DOI: 10.1155/2022/8447083] [Reference Citation Analysis]
86 Dogan I, Gurbuz M, Paksoy N, Ferhatoglu F, Vatansever S, Saip P, Demirkazik A, Aydiner A. Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC. Medicine (Baltimore) 2022;101:e30188. [PMID: 36042659 DOI: 10.1097/MD.0000000000030188] [Reference Citation Analysis]
87 Zhang R, Zhang X, Yang H, Lin Y, Wen Y, Zhao D, Chen L, Lin P, Zhang L. Ferroptosis-related lncRNAs signature to predict the survival and immune evasion for lung squamous cell carcinoma. Front Genet 2022;13:968601. [DOI: 10.3389/fgene.2022.968601] [Reference Citation Analysis]
88 Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH; ESC Scientific Document Group . 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging 2022:jeac106. [PMID: 36017575 DOI: 10.1093/ehjci/jeac106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
89 Kashizaki F, Tanaka A, Sekido Y. Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report. J Med Case Rep 2022;16:316. [PMID: 35999557 DOI: 10.1186/s13256-022-03556-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, Tan DSW, Lee DH, Misch D, Garralda E, Kim DW, van der Wekken AJ, Gainor JF, Paz-Ares L, Liu SV, Kalemkerian GP, Houvras Y, Bowles DW, Mansfield AS, Lin JJ, Smoljanovic V, Rahman A, Kong S, Zalutskaya A, Louie-Gao M, Boral AL, Mazieres J. Safety and efficacy of pralsetinib in RET fusion-positive non-small cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol 2022:S0923-7534(22)03866-2. [PMID: 35973665 DOI: 10.1016/j.annonc.2022.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
91 Lazaridis L, Schmidt T, Oster C, Blau T, Pierscianek D, Siveke JT, Bauer S, Schildhaus HU, Sure U, Keyvani K, Kleinschnitz C, Stuschke M, Herrmann K, Deuschl C, Scheffler B, Kebir S, Glas M. Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma. J Cancer Res Clin Oncol 2022. [PMID: 35953681 DOI: 10.1007/s00432-022-04050-w] [Reference Citation Analysis]
92 Tan AC, Pavlakis N. Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC). IJMS 2022;23:8863. [DOI: 10.3390/ijms23168863] [Reference Citation Analysis]
93 Shen CI, Chiang CL, Shiao TH, Luo YH, Chao HS, Huang HC, Chiu CH. Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer. Sci Rep 2022;12:13566. [PMID: 35945330 DOI: 10.1038/s41598-022-17394-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Itchins M, Pavlakis N. The quantum leap in therapeutics for advanced ALK+ non-small cell lung cancer and pursuit to cure with precision medicine. Front Oncol 2022;12:959637. [DOI: 10.3389/fonc.2022.959637] [Reference Citation Analysis]
95 Yan LD, Yang L, Li N, Wang M, Zhang YH, Zhou W, Yu ZQ, Peng XC, Cai J. Prognostic role of multiple abnormal genes in non-small-cell lung cancer. World J Clin Cases 2022; 10(22): 7772-7784 [DOI: 10.12998/wjcc.v10.i22.7772] [Reference Citation Analysis]
96 Pisapia P, Iaccarino A, De Luca C, Acanfora G, Bellevicine C, Bianco R, Daniele B, Ciampi L, De Felice M, Fabozzi T, Formisano L, Giordano P, Gridelli C, Ianniello GP, Libroia A, Maione P, Nacchio M, Pagni F, Palmieri G, Pepe F, Russo G, Salatiello M, Santaniello A, Scamarcio R, Seminati D, Troia M, Troncone G, Vigliar E, Malapelle U. Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy. IJMS 2022;23:8541. [DOI: 10.3390/ijms23158541] [Reference Citation Analysis]
97 Katakura S, Murakami S. Clinically-meaningful improvements in therapy for unresectable NSCLC. Expert Rev Anticancer Ther 2022. [PMID: 35838638 DOI: 10.1080/14737140.2022.2102483] [Reference Citation Analysis]
98 Vokes EE. 2022 Presidential Address: Advancing Equitable Cancer Care Through Innovation. J Clin Oncol 2022;:JCO2201305. [PMID: 35797507 DOI: 10.1200/JCO.22.01305] [Reference Citation Analysis]
99 Baba K, Goto Y. Lorlatinib as a treatment for ALK-positive lung cancer. Future Oncol 2022. [PMID: 35787143 DOI: 10.2217/fon-2022-0184] [Reference Citation Analysis]
100 Byun JY, Park SK, Ng BP, Liu YS, Kim CR, Park C. A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC). Expert Opin Pharmacother 2022;:1-11. [PMID: 35759783 DOI: 10.1080/14656566.2022.2095203] [Reference Citation Analysis]
101 Bokhari A, Lai W, Le A, Gabre J, Chung T, Fransson S, Bergman B, Djos A, Chen N, Martinsson T, Van den Eynden J, Doebele R, Palmer R, Hallberg B, Umapathy G. Novel Human-derived EML4-ALK Fusion Cell Lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.07.010] [Reference Citation Analysis]
102 Loh J, Ang YLE, Jain A, Yeong J, Sundar R. Targeting Anaplastic Lymphoma Kinase in GI Primary Malignancies. JCO Precis Oncol 2022;6:e2200208. [PMID: 35939772 DOI: 10.1200/PO.22.00208] [Reference Citation Analysis]
103 Scheffler M, Michels S, Nogova L. Zielgerichtete Therapie des nichtkleinzelligen Lungenkarzinoms. Innere Medizin 2022;63:700-708. [DOI: 10.1007/s00108-022-01372-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Bearz A, De Carlo E, Del Conte A, Spina M, Da Ros V, Bertoli E, Revelant A, Stanzione B, Tirelli U. The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation. IJMS 2022;23:7322. [DOI: 10.3390/ijms23137322] [Reference Citation Analysis]
105 López-Castro R, García-Peña T, Mielgo-Rubio X, Riudavets M, Teixidó C, Vilariño N, Couñago F, Mezquita L. Targeting molecular alterations in non-small-cell lung cancer: what's next? Per Med 2022. [PMID: 35748237 DOI: 10.2217/pme-2021-0059] [Reference Citation Analysis]
106 Berezina GI, Laktionov KK, Reutova EV, Ardzinba MS, Borisova TN, Utkina VL. Long-term disease control in a patient with ALK-positive non-small cell lung cancer. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-9-172-177] [Reference Citation Analysis]
107 Michelotti A, de Scordilli M, Bertoli E, De Carlo E, Del Conte A, Bearz A. NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease. Int J Mol Sci 2022;23:6748. [PMID: 35743191 DOI: 10.3390/ijms23126748] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
108 Ding K, Yi M, Liang H, Li Z, Zhang Y. Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression. Expert Rev Clin Immunol 2022;:1-13. [PMID: 35681264 DOI: 10.1080/1744666X.2022.2088510] [Reference Citation Analysis]
109 Murciano-Goroff YR, Harada G, Drilon A. An Ascendant Challenge: Central Nervous System Metastases in ALK+ Lung Cancers. Clin Cancer Res 2022;28:2477-9. [PMID: 35394532 DOI: 10.1158/1078-0432.CCR-22-0341] [Reference Citation Analysis]
110 Brenner AW, Patel AJ. Review of Current Principles of the Diagnosis and Management of Brain Metastases. Front Oncol 2022;12:857622. [PMID: 35686091 DOI: 10.3389/fonc.2022.857622] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Berlak M, Tucker E, Dorel M, Winkler A, McGearey A, Rodriguez-Fos E, da Costa BM, Barker K, Fyle E, Calton E, Eising S, Ober K, Hughes D, Koutroumanidou E, Carter P, Stankunaite R, Proszek P, Jain N, Rosswog C, Dorado-Garcia H, Molenaar JJ, Hubank M, Barone G, Anderson J, Lang P, Deubzer HE, Künkele A, Fischer M, Eggert A, Kloft C, Henssen AG, Boettcher M, Hertwig F, Blüthgen N, Chesler L, Schulte JH. Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells. Mol Cancer 2022;21:126. [PMID: 35689207 DOI: 10.1186/s12943-022-01583-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
112 Pérol M, Swalduz A. Lorlatinib in Frontline Therapy for ALK+ Advanced Non-Small-Cell Lung Cancer: Still a Matter of Debate? J Clin Oncol 2022;:JCO2200859. [PMID: 35679525 DOI: 10.1200/JCO.22.00859] [Reference Citation Analysis]
113 De Carlo E, Bertoli E, Del Conte A, Stanzione B, Berto E, Revelant A, Spina M, Bearz A. Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era. Int J Mol Sci 2022;23:6477. [PMID: 35742920 DOI: 10.3390/ijms23126477] [Reference Citation Analysis]
114 Dello Russo C, Navarra P. Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Uncontrolled Oncology Trials: A Comprehensive Review of the Literature. Front Pharmacol 2022;13:858354. [PMID: 35652050 DOI: 10.3389/fphar.2022.858354] [Reference Citation Analysis]
115 Shiba-Ishii A, Johnson TW, Dagogo-Jack I, Mino-Kenudson M, Johnson TR, Wei P, Weinrich SL, McTigue MA, Walcott MA, Nguyen-Phuong L, Dionne K, Acker A, Kiedrowski LA, Do A, Peterson JL, Barth JL, Yeap BY, Gainor JF, Lin JJ, Yoda S, Hata AN. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nat Cancer 2022;3:710-22. [PMID: 35726063 DOI: 10.1038/s43018-022-00399-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Kunz J, Wiedemann C, Grosch H, Kriegsmann K, Gryzik S, Felden J, Hundemer M, Seker-Cin H, Stenzinger M, Leo A, Stenzinger A, Thomas M, Christopoulos P. Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib. Cancers (Basel) 2022;14:2720. [PMID: 35681698 DOI: 10.3390/cancers14112720] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
117 Doi Y, Tagaya H, Noge A, Semba K. Prediction of Resistant Mutations against Upcoming ALK-TKIs, Repotrectinib (TPX-0005) and Ensartinib (X-396).. [DOI: 10.1101/2022.05.26.493531] [Reference Citation Analysis]
118 Yu Y, Zhu F, Zhang W, Lu S. Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison. J Clin Med 2022;11:2963. [PMID: 35683354 DOI: 10.3390/jcm11112963] [Reference Citation Analysis]
119 Solomon BJ, Bauer TM, Ignatius Ou S, Liu G, Hayashi H, Bearz A, Penkov K, Wu Y, Arrieta O, Jassem J, Calella AM, Peltz G, Polli A, Thurm H, Mok T. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK -Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study. JCO. [DOI: 10.1200/jco.21.02278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Mathiot L, Herbreteau G, Robin S, Fenat C, Bennouna J, Blanquart C, Denis M, Pons-tostivint E. HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature. Current Oncology 2022;29:3748-58. [DOI: 10.3390/curroncol29050300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
121 Sharma A, Low JT, Kumthekar P. Advances in the Diagnosis and Treatment of Leptomeningeal Disease. Curr Neurol Neurosci Rep 2022. [PMID: 35588045 DOI: 10.1007/s11910-022-01198-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Dagogo-Jack I, Oxnard GR, Evangelist M, Digumarthy SR, Lin JJ, Gainor JF, Murphy JF, Rabin MS, Heist RS, Muzikansky A, Shaw AT. Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse. JCO Precis Oncol 2022;6:e2100522. [PMID: 35584349 DOI: 10.1200/PO.21.00522] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
123 Cao Y, Liang Q, Lan Y, Liu Y. The therapeutic efficacy and safety improvements of crizotinib prodrug micelles on breast cancer treatment. Pharm Dev Technol 2022;:1-14. [PMID: 35579888 DOI: 10.1080/10837450.2022.2078984] [Reference Citation Analysis]
124 Goebel GL, Qiu X, Wu P. Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules. Trends Pharmacol Sci 2022:S0165-6147(22)00086-4. [PMID: 35589447 DOI: 10.1016/j.tips.2022.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Ma X, Yang S, Zhang K, Xu J, Lv P, Gao H, Qin H, Wang H, Liu X. Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. Thorac Cancer 2022. [PMID: 35560808 DOI: 10.1111/1759-7714.14455] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Raphael A, Onn A, Holtzman L, Dudnik J, Urban D, Kian W, Cohen AY, Moskovitz M, Zer A, Bar J, Rabinovich NM, Grynberg S, Oedegaard C, Agbarya A, Peled N, Shochat T, Dudnik E. The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2nd/3rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs). Front Oncol 2022;12:874712. [DOI: 10.3389/fonc.2022.874712] [Reference Citation Analysis]
127 Lin K, Lin J, Huang Z, Fu J, Yi Q, Cai J, Khan M, Yuan Y, Bu J. Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis. Front Pharmacol 2022;13:881493. [DOI: 10.3389/fphar.2022.881493] [Reference Citation Analysis]
128 Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. [DOI: 10.1038/s41571-022-00639-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
129 Alvarez-Breckenridge C, Remon J, Piña Y, Nieblas-Bedolla E, Forsyth P, Hendriks L, Brastianos PK. Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients. Am Soc Clin Oncol Educ Book 2022;42:1-19. [PMID: 35522917 DOI: 10.1200/EDBK_352320] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
130 Christofyllakis K, Monteiro AR, Cetin O, Kos IA, Greystoke A, Luciani A. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology Report. J Geriatr Oncol 2022:S1879-4068(22)00105-9. [PMID: 35525790 DOI: 10.1016/j.jgo.2022.04.013] [Reference Citation Analysis]
131 Patel RA, Coleman I, Roudier MP, Konnick EQ, Hanratty B, Dumpit R, Lucas JM, Ang LS, Low J, Tretiakova MS, Ha G, Lee JK, True LD, De Marzo AM, Nelson PS, Morrissey C, Pritchard CC, Haffner MC. Comprehensive Assessment of Anaplastic Lymphoma Kinase in Localized and Metastatic Prostate Cancer Reveals Targetable Alterations. Cancer Research Communications 2022;2:277-285. [DOI: 10.1158/2767-9764.crc-21-0156] [Reference Citation Analysis]
132 Baldacci S, Besse B, Avrillon V, Mennecier B, Mazieres J, Dubray-longeras P, Cortot AB, Descourt R, Doubre H, Quantin X, Duruisseaux M, Monnet I, Moro-sibilot D, Cadranel J, Clément-duchêne C, Cousin S, Ricordel C, Merle P, Otto J, Schneider S, Langlais A, Morin F, Westeel V, Girard N. Lorlatinib for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer: Results of the IFCT-1803 LORLATU cohort. European Journal of Cancer 2022;166:51-9. [DOI: 10.1016/j.ejca.2022.01.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
133 Tabbò F, De Filippis M, Jacobs F, Novello S. Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management. Minerva Med 2022;113. [DOI: 10.23736/s0026-4806.21.07693-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Soo RA, Huat Tan E, Hayashi H, Seto T, Lin C, Ignatius Ou S, Kim D, Liu G, Abbattista A, Martini J, Hooi Wong C, Toffalorio F, Solomon BJ. Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.05.012] [Reference Citation Analysis]
135 Oster C, Kebir S, Glas M. Meningeosis neoplastica. Onkologe 2022;28:395-404. [DOI: 10.1007/s00761-021-01073-9] [Reference Citation Analysis]
136 Griesinger F. Erstlinientherapie des metastasierten nichtkleinzelligen Lungenkarzinoms. best practice onkologie 2022;17:198-205. [DOI: 10.1007/s11654-022-00378-4] [Reference Citation Analysis]
137 Rodrigues A, Chauhan J, Sagkriotis A, Aasaithambi S, Montrone M. Understanding the lived experience of lung cancer: a European social media listening study. BMC Cancer 2022;22:475. [PMID: 35490223 DOI: 10.1186/s12885-022-09505-4] [Reference Citation Analysis]
138 Liang Y, Fang R, Rao Q. An Insight into the Medicinal Chemistry Perspective of Macrocyclic Derivatives with Antitumor Activity: A Systematic Review. Molecules 2022;27:2837. [PMID: 35566196 DOI: 10.3390/molecules27092837] [Reference Citation Analysis]
139 Kharagezov DA, Lazutin YN, Mirzoyan EA, Milakin AG, Stateshny ON, Leyman IA, Gappoeva MA, Vitkovskaya VN, Iozefi KD. Modern treatment of ALK-positive non-small cell lung cancer. jour 2022;3:41-51. [DOI: 10.37748/2686-9039-2022-3-2-5] [Reference Citation Analysis]
140 Shen Y, Lu J, Hu F, Qian J, Zhang X, Zhong R, Zhong H, Chu T, Han B. Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial. J Cancer Res Clin Oncol 2022. [PMID: 35482076 DOI: 10.1007/s00432-022-03964-9] [Reference Citation Analysis]
141 Kwon M, Ku BM, Olsen S, Park S, Lefterova M, Odegaard J, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors. Cancer Med 2022. [PMID: 35437925 DOI: 10.1002/cam4.4663] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
142 Jiang Y, Wang Y, Fu S, Chen T, Zhou Y, Zhang X, Chen C, He LN, Du W, Li H, Lin Z, Zhao Y, Yang Y, Zhao H, Fang W, Huang Y, Hong S, Zhang L. A CT-based radiomics model to predict subsequent brain metastasis in patients with ALK-rearranged non-small cell lung cancer undergoing crizotinib treatment. Thorac Cancer 2022. [PMID: 35437945 DOI: 10.1111/1759-7714.14386] [Reference Citation Analysis]
143 Tao Y, Zhou Y, Tang L, Chen H, Feng Y, Shi Y. Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis. Invest New Drugs. [DOI: 10.1007/s10637-022-01242-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Liu Y, Chen C, Rong C, He X, Chen L. Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study. Front Pharmacol 2022;13:858279. [PMID: 35370632 DOI: 10.3389/fphar.2022.858279] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
145 Cherny N, Dafni U, Pentheroudakis G, Piccart M, Zygoura P, Gyawali B, de Vries E. “The first ones now, will later be last”: understanding the importance of historical context when reading ESMO-MCBS scores. ESMO Open 2022;7:100413. [DOI: 10.1016/j.esmoop.2022.100413] [Reference Citation Analysis]
146 Bauer TM, Bertino EM. Podcast on the Management of Adverse Events Associated with Lorlatinib. Adv Ther 2022;39:1447-56. [PMID: 35147918 DOI: 10.1007/s12325-022-02050-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Abughanimeh O, Kaur A, Osta BE, Ganti AK. Novel targeted therapies for advanced non-small lung cancer. Seminars in Oncology 2022. [DOI: 10.1053/j.seminoncol.2022.03.003] [Reference Citation Analysis]
148 Girard N, Galland-girodet S, Avrillon V, Besse B, Duruisseaux M, Cadranel J, Otto J, Prevost A, Roch B, Bennouna J, Bouledrak K, Coudurier M, Egenod T, Lamy R, Ricordel C, Moro-sibilot D, Odier L, Tillon-strozyk J, Zalcman G, Missy P, Westeel V, Baldacci S. Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study. ESMO Open 2022;7:100418. [DOI: 10.1016/j.esmoop.2022.100418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
149 Li AY, Gaebe K, Jerzak KJ, Cheema PK, Sahgal A, Das S. Intracranial Metastatic Disease: Present Challenges, Future Opportunities. Front Oncol 2022;12:855182. [PMID: 35330715 DOI: 10.3389/fonc.2022.855182] [Reference Citation Analysis]
150 Benjamin DJ, Haslam A, Gill J, Prasad V. Targeted therapy in lung cancer: Are we closing the gap in years of life lost? Cancer Med 2022. [PMID: 35315222 DOI: 10.1002/cam4.4703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Rubino S, Oliver DE, Tran ND, Vogelbaum MA, Forsyth PA, Yu HM, Ahmed K, Etame AB. Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies. Front Oncol 2022;12:854402. [PMID: 35311078 DOI: 10.3389/fonc.2022.854402] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
152 Shimizu Y, Okada K, Adachi J, Abe Y, Narumi R, Uchibori K, Yanagitani N, Koike S, Takagi S, Nishio M, Fujita N, Katayama R. GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer. NPJ Precis Oncol 2022;6:16. [PMID: 35301419 DOI: 10.1038/s41698-022-00260-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
153 Mithoowani H, Febbraro M. Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology. Current Oncology 2022;29:1828-39. [DOI: 10.3390/curroncol29030150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
154 Bonanno L, Dal Maso A, Pavan A, Zulato E, Calvetti L, Pasello G, Guarneri V, Conte P, Indraccolo S. Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg? Br J Cancer 2022. [PMID: 35264788 DOI: 10.1038/s41416-022-01777-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
155 Ma L, Xiao J, Guan Y, Wu D, Gu T, Wang J. SDK1-ALK Fusion in a Lung Adenocarcinoma Patient With Excellent Response to ALK Inhibitor Treatment: A Case Report. Front Oncol 2022;12:860060. [DOI: 10.3389/fonc.2022.860060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Fallet V, Rouby P, Ahle G, Arrondeau J, Naltet C, Duflot-boukobza A, De Crozals F, Lena H, Cortot A. Troubles du système nerveux central sous lorlatinib : comment les détecter et les gérer en pratique ? Bulletin du Cancer 2022. [DOI: 10.1016/j.bulcan.2022.01.011] [Reference Citation Analysis]
157 Liu S, Shi J, Li H, Li J, Zhu Y, Li B, Sun Y. Development of a biotin–streptavidin-enhanced enzyme-linked immunosorbent assay (BA-ELISA) for high-throughput screening of KRASG12C inhibitors. SLAS Discovery 2022;27:107-113. [DOI: 10.1016/j.slasd.2021.12.007] [Reference Citation Analysis]
158 Tan AC, Tan SH, Zhou S, Peters S, Curigliano G, Tan DS. Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis. Cancer Treatment Reviews 2022;104:102354. [DOI: 10.1016/j.ctrv.2022.102354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
159 Leighow SM, Landry B, Lee MJ, Peyton SR, Pritchard JR. Agent-based models help interpret patterns of clinical drug resistance by contextualizing competition between distinct drug failure modes.. [DOI: 10.1101/2022.02.25.481999] [Reference Citation Analysis]
160 Yanagimura N, Takeuchi S, Fukuda K, Arai S, Tanimoto A, Nishiyama A, Ogo N, Takahashi H, Asai A, Watanabe S, Kikuchi T, Yano S. STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis. npj Precis Onc 2022;6. [DOI: 10.1038/s41698-022-00254-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Fukui T, Tachihara M, Nagano T, Kobayashi K. Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer. Cancers (Basel) 2022;14:1184. [PMID: 35267492 DOI: 10.3390/cancers14051184] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
162 Tan AC, Tan DSW. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J Clin Oncol 2022;40:611-25. [PMID: 34985916 DOI: 10.1200/JCO.21.01626] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 29.0] [Reference Citation Analysis]
163 Tsui DCC, Camidge DR, Rusthoven CG. Managing Central Nervous System Spread of Lung Cancer: The State of the Art. J Clin Oncol 2022;40:642-60. [PMID: 34985937 DOI: 10.1200/JCO.21.01715] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
164 Hua G, Zhang X, Zhang M, Wang Q, Chen X, Yu R, Bao H, Liu J, Wu X, Shao Y, Liang B, Lu K. Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients. ESMO Open 2022;7:100337. [PMID: 35123209 DOI: 10.1016/j.esmoop.2021.100337] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
165 Yun KM, Bazhenova LA. Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC. CMAR 2022;Volume 14:843-50. [DOI: 10.2147/cmar.s283199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Lin SY, Tsan DL, Chuang CC, Yang CC, Pai PC, Wang CL, Wu YM, Lee CC, Lin CH, Wei KC, Chou WC. Oncological Outcomes After Hippocampus-Sparing Whole-Brain Radiotherapy in Cancer Patients With Newly Diagnosed Brain Oligometastases: A Single-Arm Prospective Observational Cohort Study in Taiwan. Front Oncol 2021;11:784635. [PMID: 35096584 DOI: 10.3389/fonc.2021.784635] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
167 Harris JP, Fujimoto DK, Nagasaka M, Ku E, Harada G, Keshava H, Mahtabifard A, Longoria J, Patel N, Seyedin S, Simon A, Chen A. Controversies in lung cancer: heterogeneity in treatment recommendations for stage III NSCLC according to disease burden and oncogenic driver alterations. Clinical Lung Cancer 2022. [DOI: 10.1016/j.cllc.2022.02.001] [Reference Citation Analysis]
168 Pisano C, De Filippis M, Jacobs F, Novello S, Reale ML. Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements. Cancers (Basel) 2022;14:718. [PMID: 35158987 DOI: 10.3390/cancers14030718] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
169 Shi Y, Fang J, Hao X, Zhang S, Liu Y, Wang L, Chen J, Hu Y, Hang X, Li J, Liu C, Zhang Y, Wang Z, Hu Y, Gu K, Huang J, Zhang L, Shan J, Ouyang W, Zhao Y, Zhuang W, Yu Y, Zhao J, Zhang H, Lu P, Li W, Si M, Ge M, Geng H. Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial. Signal Transduct Target Ther 2022;7:25. [PMID: 35087031 DOI: 10.1038/s41392-021-00841-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Shen E, Van Swearingen AED, Price MJ, Bulsara K, Verhaak RGW, Baëta C, Painter BD, Reitman ZJ, Salama AKS, Clarke JM, Anders CK, Fecci PE, Goodwin CR, Walsh KM. A Need for More Molecular Profiling in Brain Metastases. Front Oncol 2022;11:785064. [DOI: 10.3389/fonc.2021.785064] [Reference Citation Analysis]
171 Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer 2022;21. [DOI: 10.1186/s12943-021-01489-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 56] [Article Influence: 47.0] [Reference Citation Analysis]
172 Berk Ş, Kaya S, Akkol EK, Bardakçı H. A comprehensive and current review on the role of flavonoids in lung cancer-Experimental and theoretical approaches. Phytomedicine 2022;98:153938. [PMID: 35123170 DOI: 10.1016/j.phymed.2022.153938] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
173 Skribek M, Rounis K, Tsakonas G, Ekman S. Complications following novel therapies for non-small cell lung cancer. J Intern Med 2022. [PMID: 35032058 DOI: 10.1111/joim.13445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Schokrpur S, Patel S. Molecularly directed therapy of advanced/metastatic non-small cell lung cancer. International Journal of Cancer Care and Delivery 2022;2. [DOI: 10.53876/001c.31316] [Reference Citation Analysis]
175 Lin S, Gong J, Canas GC, Winkle P, Pelletier K, LaBadie RR, Ginman K, Pithavala YK. A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment. Eur J Drug Metab Pharmacokinet 2022. [PMID: 35018553 DOI: 10.1007/s13318-021-00747-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
176 Cameron LB, Hitchen N, Chandran E, Morris T, Manser R, Solomon BJ, Jordan V. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cochrane Database Syst Rev 2022;1:CD013453. [PMID: 34994987 DOI: 10.1002/14651858.CD013453.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
177 Chen X, Hong X, Chen G, Xue J, Huang J, Wang F, Ali WADS, Li J, Zhang L. The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor. Transl Oncol 2022;17:101338. [PMID: 34999541 DOI: 10.1016/j.tranon.2021.101338] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
178 Cheng Y, Zhang T, Xu Q. Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. MedComm (2020) 2021;2:692-729. [PMID: 34977873 DOI: 10.1002/mco2.105] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
179 Bauman JR, Edelman MJ. Targeted Therapies in Non-small Cell Lung Cancer. Medical Radiology 2022. [DOI: 10.1007/174_2022_312] [Reference Citation Analysis]
180 Jalal SI, Mamdani H, Turchi AM, Turchi JJ. Lung Cancer. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00063-3] [Reference Citation Analysis]
181 Steiger HJ, Vollmer K, Rogers S, Schwyzer L. State of affairs regarding targeted pharmacological therapy of cancers metastasized to the brain. Neurosurg Rev 2022;45:3119-38. [PMID: 35902427 DOI: 10.1007/s10143-022-01839-8] [Reference Citation Analysis]
182 Gomes F, Banfill K, Bille A, Fraser S, Banna G. Non-Small Cell Lung Cancer in Older Adults with Frailty. Frailty in Older Adults with Cancer 2022. [DOI: 10.1007/978-3-030-89162-6_18] [Reference Citation Analysis]
183 Morgensztern D. Genomic Alterations in Lung Cancer. Medical Radiology 2022. [DOI: 10.1007/174_2022_298] [Reference Citation Analysis]
184 Geng D, Guo Q, Huang S, Zhang H, Guo S, Li X. A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer. Technol Cancer Res Treat 2022;21:15330338221078429. [PMID: 35289201 DOI: 10.1177/15330338221078429] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
185 申 越. Research Progress on Small Molecules Targeted Therapy in Non-Small Cell Lung Cancer. WJCR 2022;12:90-98. [DOI: 10.12677/wjcr.2022.122012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
186 Coleman N, Harbery A, Heuss S, Vivanco I, Popat S. Targeting un-MET needs in advanced non-small cell lung cancer. Lung Cancer 2021;164:56-68. [PMID: 35033939 DOI: 10.1016/j.lungcan.2021.12.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
187 Sharma A, Singer L, Kumthekar P. Updates on Molecular Targeted Therapies for Intraparenchymal CNS Metastases. Cancers 2021;14:17. [DOI: 10.3390/cancers14010017] [Reference Citation Analysis]
188 Wang Y, Wang T, Xue J, Jia Z, Liu X, Li B, Li J, Li X, Wang W, Bing Z, Cao L, Cao Z, Liang N. Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report. Front Pharmacol 2021;12. [DOI: 10.3389/fphar.2021.809467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
189 Laktionov KK, Reutova EV, Kruteleva SY, Antonova EY. Efficacy of lorlatinib in the treatment of ALK-positive non-small cell lung cancer patients with progression on crizotinib: personal experience. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-20-62-67] [Reference Citation Analysis]
190 Zhou J, Jiang X, Xia HA, Wei P, Hobbs BP. Predicting outcomes of phase III oncology trials with Bayesian mediation modeling of tumor response. Stat Med 2021. [PMID: 34888892 DOI: 10.1002/sim.9268] [Reference Citation Analysis]
191 Lin JJ, Muzikansky A, Kennedy E, Kuberski H, Stober LL, Wanat AC, Azzoli CG, Lennes I, Sequist LV, Dagogo-Jack I, Shaw AT, Gainor JF. Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study. ESMO Open 2021;7:100342. [PMID: 34896762 DOI: 10.1016/j.esmoop.2021.100342] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
192 Angeles AK, Christopoulos P, Yuan Z, Bauer S, Janke F, Ogrodnik SJ, Reck M, Schlesner M, Meister M, Schneider MA, Dietz S, Stenzinger A, Thomas M, Sültmann H. Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis. NPJ Precis Oncol 2021;5:100. [PMID: 34876698 DOI: 10.1038/s41698-021-00239-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
193 Myall NJ, Yu H, Soltys SG, Wakelee HA, Pollom E. Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies. Neurooncol Adv 2021;3:v52-62. [PMID: 34859233 DOI: 10.1093/noajnl/vdab106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
194 Khan M, Zhao Z, Li X, Liao G. Anti-PD1 Therapy Plus Whole-Brain Radiation Therapy May Prolong PFS in Selected Non-Small Cell Lung Cancer Patients with Brain Metastases: A Retrospective Study. Int J Gen Med 2021;14:8903-18. [PMID: 34858054 DOI: 10.2147/IJGM.S333890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
195 Coleman N, Hong L, Zhang J, Heymach J, Hong D, Le X. Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer. ESMO Open 2021;6:100319. [PMID: 34837746 DOI: 10.1016/j.esmoop.2021.100319] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
196 Ma HC, Liu YH, Ding KL, Liu YF, Zhao WJ, Zhu YJ, Chang XS, Chen YD, Xiao ZZ, Yu YY, Zhou R, Zhang HB. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials. BMC Cancer 2021;21:1278. [PMID: 34836510 DOI: 10.1186/s12885-021-08977-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
197 Peng L, Lu D, Xia Y, Hong S, Selvaggi G, Stebbing J, Sun Y, Liang F. Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis. Front Oncol 2021;11:754768. [PMID: 34820326 DOI: 10.3389/fonc.2021.754768] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
198 Maillard M, Louveau B, Vilquin P, Goldwirt L, Thomas F, Mourah S. Pharmacogenomics in solid cancers and hematologic malignancies: Improving personalized drug prescription. Therapie 2021:S0040-5957(21)00241-9. [PMID: 34922740 DOI: 10.1016/j.therap.2021.11.003] [Reference Citation Analysis]
199 Takeda T, Yamada T, Tanimura K, Nakano T, Ishida M, Tachibana Y, Shiotsu S, Horiuchi S, Hibino M, Okada A, Chihara Y, Takayama K. Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib. Diagnostics (Basel) 2021;11:2170. [PMID: 34943412 DOI: 10.3390/diagnostics11122170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
200 Kwan TY, Chowdhury EH. Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients. Medicina (Kaunas) 2021;57:1252. [PMID: 34833470 DOI: 10.3390/medicina57111252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
201 Allen TC, Xiao Y, Yang B, Croix D, Abraham A, Redpath S, Engstrom-Melynk J, Shah R, Madala J, Bernicker EH. Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States: retrospective real world data. Oncotarget 2021;12:2308-15. [PMID: 34786182 DOI: 10.18632/oncotarget.28114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
202 Yang S, Xiao J, Liu Q, Zhang Y, Bi N, Huang X, Chen X, Wang K, Ma Y, Deng L, Wang W, Zhao R, Li J, Yi J, Wang S, Li Y. The Sequence of Intracranial Radiotherapy and Systemic Treatment With Tyrosine Kinase Inhibitors for Gene-Driven Non-Small Cell Lung Cancer Brain Metastases in the Targeted Treatment Era: A 10-Year Single-Center Experience. Front Oncol 2021;11:732883. [PMID: 34722275 DOI: 10.3389/fonc.2021.732883] [Reference Citation Analysis]
203 Dagogo-Jack I. Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancer-A Likely Limited Role on a Deep Bench. JAMA Oncol 2021;7:1615-6. [PMID: 34473198 DOI: 10.1001/jamaoncol.2021.3369] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
204 Hu J, Xing K, Zhang Y, Liu M, Wang Z. Global Research Trends in Tyrosine Kinase Inhibitors: Coword and Visualization Study (Preprint).. [DOI: 10.2196/preprints.34548] [Reference Citation Analysis]
205 Hu J, Xing K, Zhang Y, Liu M, Wang Z. Global research Trends in Tyrosine Kinase Inhibitors: A Co-Word and Visualized Study (Preprint). JMIR Medical Informatics. [DOI: 10.2196/34548] [Reference Citation Analysis]
206 Hibma JE, O'Gorman M, Nepal S, Pawlak S, Ginman K, Pithavala YK. Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants. Cancer Chemother Pharmacol 2021. [PMID: 34698901 DOI: 10.1007/s00280-021-04368-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
207 Pellerino A, Bruno F, Rudà R, Soffietti R. Systemic Therapy for Lung Cancer Brain Metastases. Curr Treat Options Oncol 2021;22:110. [PMID: 34693454 DOI: 10.1007/s11864-021-00911-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
208 Ichihara E. An Update on Targeted Therapy in Advanced Non-small Cell Lung Cancer. JJLC 2021;61:377-382. [DOI: 10.2482/haigan.61.377] [Reference Citation Analysis]
209 Zoccarato M, Grisold W, Grisold A, Poretto V, Boso F, Giometto B. Paraneoplastic Neuropathies: What's New Since the 2004 Recommended Diagnostic Criteria. Front Neurol 2021;12:706169. [PMID: 34659082 DOI: 10.3389/fneur.2021.706169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
210 Pan Y, Deng C, Qiu Z, Cao C, Wu F. The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer. Front Oncol 2021;11:713530. [PMID: 34660278 DOI: 10.3389/fonc.2021.713530] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
211 da Cunha IW, de Almeida Coudry R, de Macedo MP, de Assis EACP, Stefani S, Soares FA. A call to action: molecular pathology in Brazil. Surg Exp Pathol 2021;4. [DOI: 10.1186/s42047-021-00096-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
212 Zhao B, Han Y, Wang Y, Wang Y, Wang Y, Xing H, Dai C, Wang Y, Wang H, Ma W. A Bayesian network meta-analysis regarding the comparative efficacy of therapeutics for ALK-positive, brain metastatic non-small cell lung cancer. Pharmacol Res 2021;174:105931. [PMID: 34626769 DOI: 10.1016/j.phrs.2021.105931] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
213 Sheng J, Li H, Yu X, Yu S, Chen K, Pan G, Xie M, Li N, Zhou Z, Fan Y. Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China. Thorac Cancer 2021;12:3019-31. [PMID: 34596346 DOI: 10.1111/1759-7714.14171] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
214 Choudhury NJ, Schneider JL, Patil T, Zhu VW, Goldman DA, Yang SR, Falcon CJ, Do A, Nie Y, Plodkowski AJ, Chaft JE, Digumarthy SR, Rekhtman N, Arcila ME, Iasonos A, Ou SI, Lin JJ, Drilon A. Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers. JTO Clin Res Rep 2021;2:100187. [PMID: 34590036 DOI: 10.1016/j.jtocrr.2021.100187] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
215 Zhu VW, Nagasaka M, Madison R, Schrock AB, Cui J, Ou SI. A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review. JTO Clin Res Rep 2021;2:100116. [PMID: 34589977 DOI: 10.1016/j.jtocrr.2020.100116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
216 Khouri C, Hlavaty A, Roustit M, Cracowski JL, Chaumais MC, Humbert M, Montani D. Investigating the association between ALK receptor tyrosine kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database. Eur Respir J 2021;58:2101576. [PMID: 34588195 DOI: 10.1183/13993003.01576-2021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
217 Maurer TS, Edwards M, Hepworth D, Verhoest P, Allerton CMN. Designing small molecules for therapeutic success: A contemporary perspective. Drug Discov Today 2021:S1359-6446(21)00424-4. [PMID: 34601124 DOI: 10.1016/j.drudis.2021.09.017] [Reference Citation Analysis]
218 Wu KL, Chen HL, Tsai YM, Lee TH, Chang HM, Tsai YC, Chuang CH, Chang YC, Tu YK, Yang CJ, Hung JY, Chong IW. First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis. J Clin Med 2021;10:4376. [PMID: 34640394 DOI: 10.3390/jcm10194376] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
219 Lu J, Zhang Y, Lou Y, Yan B, Zou B, Hu M, Wang Y, Chen Y, Yang Z, Wang H, Zhang W, Han B. ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients. Front Genet 2021;12:723670. [PMID: 34557222 DOI: 10.3389/fgene.2021.723670] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
220 Kemper M, Evers G, Schulze AB, Sperveslage J, Schülke C, Lenz G, Herold T, Hartmann W, Schildhaus HU, Bleckmann A. Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition. Oncotarget 2021;12:1946-52. [PMID: 34548910 DOI: 10.18632/oncotarget.28062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
221 Orlov-Slavu MC, Popa AM, Tulin A, Pantea Stoian A, Poiana C, Paleru C, Calu V, Nitipir C. The Utility of Next-Generation Sequencing in the Treatment Decision-Making for Metastatic Non-Small-Cell Lung Cancer. Cureus 2021;13:e16919. [PMID: 34513491 DOI: 10.7759/cureus.16919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
222 Weis LN, Tolaney SM, Barrios CH, Barroso-Sousa R. Tissue-agnostic drug approvals: how does this apply to patients with breast cancer? NPJ Breast Cancer 2021;7:120. [PMID: 34518552 DOI: 10.1038/s41523-021-00328-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
223 Angeli E, Bousquet G. Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Blood-Brain Barrier. Pharmaceutics 2021;13:1446. [PMID: 34575525 DOI: 10.3390/pharmaceutics13091446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
224 Feng C, Zhou R, Liu F, Wang T, Liu S, Shao Y. STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report. Front Oncol 2021;11:700341. [PMID: 34490099 DOI: 10.3389/fonc.2021.700341] [Reference Citation Analysis]
225 Horn L, Wang Z, Wu G, Poddubskaya E, Mok T, Reck M, Wakelee H, Chiappori AA, Lee DH, Breder V, Orlov S, Cicin I, Cheng Y, Liu Y, Fan Y, Whisenant JG, Zhou Y, Oertel V, Harrow K, Liang C, Mao L, Selvaggi G, Wu YL. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA Oncol 2021. [PMID: 34473194 DOI: 10.1001/jamaoncol.2021.3523] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 19.5] [Reference Citation Analysis]
226 Baldacci S, Mascaux C, Cortot A. Oncogenèse pulmonaire : mécanismes généraux et addictions oncogéniques. Revue des Maladies Respiratoires Actualités 2021;13:2S12-2S20. [DOI: 10.1016/s1877-1203(21)00091-4] [Reference Citation Analysis]
227 Mogenet A, Greillier L, Tomasini P. The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer. Pharmgenomics Pers Med 2021;14:987-96. [PMID: 34429632 DOI: 10.2147/PGPM.S267437] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
228 Waliany S, Zhu H, Wakelee H, Padda SK, Das M, Ramchandran K, Myall NJ, Chen T, Witteles RM, Neal JW. Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC. J Thorac Oncol 2021;16:2029-39. [PMID: 34418561 DOI: 10.1016/j.jtho.2021.07.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
229 Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med 2021;27:1345-56. [PMID: 34385702 DOI: 10.1038/s41591-021-01450-2] [Cited by in Crossref: 73] [Cited by in F6Publishing: 81] [Article Influence: 36.5] [Reference Citation Analysis]
230 Ando K, Manabe R, Kishino Y, Kusumoto S, Yamaoka T, Tanaka A, Ohmori T, Sagara H. Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis. Cancers (Basel) 2021;13:3704. [PMID: 34359604 DOI: 10.3390/cancers13153704] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
231 Shiba-ishii A, Johnson TW, Dagogo-jack I, Mino-kenudson M, Johnson TR, Wei P, Weinrich SL, Mctigue MA, Walcott MA, Nguyen-phuong L, Dionne K, Acker A, Kiedrowski L, Do A, Peterson JL, Barth JL, Yeap BY, Gainor JF, Lin JJ, Yoda S, Hata AN. Structural and functional analysis of lorlatinib analogs reveals roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.. [DOI: 10.1101/2021.07.16.452681] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
232 Majeed U, Manochakian R, Zhao Y, Lou Y. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. J Hematol Oncol 2021;14:108. [PMID: 34238332 DOI: 10.1186/s13045-021-01121-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 40] [Article Influence: 15.5] [Reference Citation Analysis]
233 Battisti NML, Decoster L, Williams GR, Kanesvaran R, Wildiers H, Ring A. Targeted Therapies in Older Adults With Solid Tumors. J Clin Oncol 2021;39:2128-37. [PMID: 34043448 DOI: 10.1200/JCO.21.00132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
234 Testa S, Million L, Longacre T, Bui N. Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib. Case Rep Oncol 2021;14:812-9. [PMID: 34248545 DOI: 10.1159/000516758] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
235 Pellerino A, Brastianos PK, Rudà R, Soffietti R. Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches. Cancers (Basel) 2021;13:2888. [PMID: 34207653 DOI: 10.3390/cancers13122888] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
236 Stein MK, Oluoha O, Patel K, VanderWalde A. Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. J Pers Med 2021;11:518. [PMID: 34198738 DOI: 10.3390/jpm11060518] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
237 Roosan MR, Mambetsariev I, Pharaon R, Fricke J, Baroz AR, Chao J, Chen C, Nasser MW, Chirravuri-Venkata R, Jain M, Smith L, Yost SE, Reckamp KL, Pillai R, Arvanitis L, Afkhami M, Wang EW, Chung V, Cristea M, Fakih M, Koczywas M, Massarelli E, Mortimer J, Yuan Y, Batra SK, Pal S, Salgia R. Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. Cancers (Basel) 2021;13:2776. [PMID: 34204917 DOI: 10.3390/cancers13112776] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
238 Li S, Li J, Peng L, Li Y, Wan X. Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. Front Oncol 2021;11:684073. [PMID: 34136409 DOI: 10.3389/fonc.2021.684073] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
239 Ali S, Górska Z, Duchnowska R, Jassem J. Molecular Profiles of Brain Metastases: A Focus on Heterogeneity. Cancers (Basel) 2021;13:2645. [PMID: 34071176 DOI: 10.3390/cancers13112645] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
240 Filipska M, Rosell R. Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment. Mol Oncol 2021;15:1667-82. [PMID: 33969622 DOI: 10.1002/1878-0261.12983] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
241 Sugiyama K, Izumika A, Iwakoshi A, Nishibori R, Sato M, Shiraishi K, Hattori H, Nishimura R, Kitagawa C. Successful Alectinib Treatment for Carcinoma of Unknown Primary with EML4-ALK Fusion Gene: A Case Report. Curr Oncol 2021;28:1938-45. [PMID: 34064158 DOI: 10.3390/curroncol28030180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
242 Cohen P, Cross D, Jänne PA. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov 2021;20:551-69. [PMID: 34002056 DOI: 10.1038/s41573-021-00195-4] [Cited by in Crossref: 174] [Cited by in F6Publishing: 187] [Article Influence: 87.0] [Reference Citation Analysis]
243 Antoni D, Burckel H, Noel G. Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview. Cancers (Basel) 2021;13:2394. [PMID: 34063424 DOI: 10.3390/cancers13102394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
244 Kim JH. Prognostic and predictive markers in glioblastoma and ALK overexpression. J Pathol Transl Med 2021;55:236-7. [PMID: 34015889 DOI: 10.4132/jptm.2021.04.29] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
245 Bernicker EH, Xiao Y, Abraham A, Yang B, Croix DA, Redpath S, Engstrom-Melnyk J, Shah R, Madala J, Allen TC. Adherence to National Comprehensive Cancer Network ALK Testing Guidelines for Patients with Advanced Non-Small Cell Lung Cancer in U.S. Community Medical Centers. Oncologist 2021;26:e1050-7. [PMID: 33823082 DOI: 10.1002/onco.13779] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
246 He X, Jiao XD, Liu K, Qin BD, Wu Y, Ling Y, Liu J, Xu AQ, Song K, Zang YS. Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case Report. JCO Precis Oncol 2021;5:PO. [PMID: 34036227 DOI: 10.1200/PO.20.00534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
247 Christopoulos P, Dietz S, Angeles AK, Rheinheimer S, Kazdal D, Volckmar AL, Janke F, Endris V, Meister M, Kriegsmann M, Zemojtel T, Reck M, Stenzinger A, Thomas M, Sültmann H. Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies. Transl Lung Cancer Res 2021;10:2118-31. [PMID: 34164264 DOI: 10.21037/tlcr-21-32] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
248 Ren AL, Digby RJ, Needham EJ. Neurological update: COVID-19. J Neurol 2021. [PMID: 33929617 DOI: 10.1007/s00415-021-10581-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
249 Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non-small cell lung cancer: Past, present and future . World J Clin Oncol 2021; 12(4): 217-237 [PMID: 33959476 DOI: 10.5306/wjco.v12.i4.217] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 27] [Article Influence: 15.0] [Reference Citation Analysis]
250 Elsayed M, Bozorgmehr F, Kazdal D, Volckmar AL, Sültmann H, Fischer JR, Kriegsmann M, Stenzinger A, Thomas M, Christopoulos P. Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer. Front Oncol 2021;11:670483. [PMID: 33959513 DOI: 10.3389/fonc.2021.670483] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
251 Chuang CH, Chen HL, Chang HM, Tsai YC, Wu KL, Chen IH, Chen KC, Lee JY, Chang YC, Chen CL, Tu YK, Hung JY, Yang CJ, Chong IW. Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer. Cancers (Basel) 2021;13:1966. [PMID: 33921762 DOI: 10.3390/cancers13081966] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
252 Lazarus KA, Pennycuick A, Hynds RE, Janes SM. Stem cells and lung cancer. Lung Stem Cells in Development, Health and Disease 2021. [DOI: 10.1183/2312508x.10010720] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
253 Krome S. Lorlatinib mit hoher intrakranieller Ansprechrate. Onkologische Welt 2021;12:106-106. [DOI: 10.1055/a-1404-8725] [Reference Citation Analysis]
254 Matos LL, Forster CHQ, Marta GN, Castro Junior G, Ridge JA, Hirata D, Miranda-Filho A, Hosny A, Sanabria A, Gregoire V, Patel SG, Fagan JJ, D'Cruz AK, Licitra L, Mehanna H, Hao SP, Psyrri A, Porceddu S, Galloway TJ, Golusinski W, Lee NY, Shiguemori EH, Matieli JE, Shiguemori APAC, Diamantino LR, Schiaveto LF, Leão L, Castro AF, Carvalho AL, Kowalski LP. The hidden curve behind COVID-19 outbreak: the impact of delay in treatment initiation in cancer patients and how to mitigate the additional risk of dying-the head and neck cancer model. Cancer Causes Control 2021;32:459-71. [PMID: 33704627 DOI: 10.1007/s10552-021-01411-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
255 Chang C, Sun X, Wang G, Yu H, Zhao W, Ge Y, Duan S, Qian X, Wang R, Lei B, Wang L, Liu L, Ruan M, Yan H, Liu C, Chen J, Xie W. A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts ALK Rearrangement Status in Lung Adenocarcinoma. Front Oncol 2021;11:603882. [PMID: 33738250 DOI: 10.3389/fonc.2021.603882] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
256 Schalhorn A. Neuer ALK-TKI auch bei ZNS-Metastasen effektiv. InFo Hämatol Onkol 2021;24:24-25. [DOI: 10.1007/s15004-021-8583-0] [Reference Citation Analysis]
257 Mizuta H, Okada K, Araki M, Adachi J, Takemoto A, Kutkowska J, Maruyama K, Yanagitani N, Oh-Hara T, Watanabe K, Tamai K, Friboulet L, Katayama K, Ma B, Sasakura Y, Sagae Y, Kukimoto-Niino M, Shirouzu M, Takagi S, Simizu S, Nishio M, Okuno Y, Fujita N, Katayama R. Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. Nat Commun 2021;12:1261. [PMID: 33627640 DOI: 10.1038/s41467-021-21396-w] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
258 Zeymer U, Gitt A, Thiele H. [COVID-19 pandemic : Effects on clinical care of cardiovascular patients in spring 2020]. Herz 2021;46:115-9. [PMID: 33590283 DOI: 10.1007/s00059-020-05015-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
259 Smolle E, Taucher V, Lindenmann J, Jost PJ, Pichler M. Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer. Cancers (Basel) 2021;13:699. [PMID: 33572278 DOI: 10.3390/cancers13040699] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
260 Elsayed M, Christopoulos P. Therapeutic Sequencing in ALK+ NSCLC. Pharmaceuticals (Basel) 2021;14:80. [PMID: 33494549 DOI: 10.3390/ph14020080] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
261 Ueda S, Shukuya T, Hayashi T, Suzuki M, Kondo A, Arai Y, Takeshige T, Ninomiya H, Takahashi K. Transformation from adenocarcinoma to squamous cell lung carcinoma with MET amplification after lorlatinib resistance: A case report. Thorac Cancer 2021;12:715-9. [PMID: 33475256 DOI: 10.1111/1759-7714.13829] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
262 Kounnis V, Cleland J, Azam F, Midgley R, Kerr DJ. Biomarkers in oncology. Principles of Translational Science in Medicine 2021. [DOI: 10.1016/b978-0-12-820493-1.00012-x] [Reference Citation Analysis]
263 Laktionov K, Breder V, Bolotina L, Vladimirova L, Gordiev M, Demidova I, Moiseenko F, Orlov S, Reutova E, Savelov N, Sakaeva D, Smolin A. ALK-, ROS1-, RET-, and NTRK-positive non-small cell lung cancer: diagnosis and targeted therapy. Resolution of the Expert Panel. Onkol Z im P A Gercena 2021;10:41. [DOI: 10.17116/onkolog20211004141] [Reference Citation Analysis]
264 Corre R. Tumors: Non-small Cell Lung Cancer. Encyclopedia of Gerontology and Population Aging 2021. [DOI: 10.1007/978-3-319-69892-2_779-1] [Reference Citation Analysis]
265 Corre R. Tumors: Non-small Cell Lung Cancer. Encyclopedia of Gerontology and Population Aging 2021. [DOI: 10.1007/978-3-030-22009-9_779] [Reference Citation Analysis]
266 de Lorenzo Alvarez A, Revilla Á, Corbalán T, Villar A, Espinel L, Martins J, Cubas A. Ischemic stroke and purpuric dermatitis as COVID-19-related complications in a peritoneal dialysis patient. CEN Case Rep 2021;10:250-4. [PMID: 33205335 DOI: 10.1007/s13730-020-00553-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
267 Matsushita K, Hess S, Marchandot B, Sato C, Truong DP, Kim NT, Weiss A, Jesel L, Ohlmann P, Morel O. Clinical features of patients with acute coronary syndrome during the COVID-19 pandemic. J Thromb Thrombolysis 2021;52:95-104. [PMID: 33200333 DOI: 10.1007/s11239-020-02340-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
268 Lairez O, Blanchard V, Houard V, Vardon-Bounes F, Lemasle M, Cariou E, Lavie-Badie Y, Ruiz S, Cazalbou S, Delmas C, Georges B, Galinier M, Carrié D, Conil JM, Minville V. Cardiac imaging phenotype in patients with coronavirus disease 2019 (COVID-19): results of the cocarde study. Int J Cardiovasc Imaging 2021;37:449-57. [PMID: 32902783 DOI: 10.1007/s10554-020-02010-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
269 Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol 2020;16:636-44. [PMID: 32839585 DOI: 10.1038/s41582-020-0398-3] [Cited by in Crossref: 213] [Cited by in F6Publishing: 229] [Article Influence: 71.0] [Reference Citation Analysis]
270 Cani I, Barone V, D'Angelo R, Pisani L, Allegri V, Spinardi L, Malpassi P, Fasano L, Rinaldi R, Fanti S, Cortelli P, Guarino M. Frontal encephalopathy related to hyperinflammation in COVID-19. J Neurol 2021;268:16-9. [PMID: 32654063 DOI: 10.1007/s00415-020-10057-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]